Fabry disease involves deficient or dysfunctional alpha-galactosidase A, an enzyme that works in lysosomes. It is associated with disease-causing variants in GLA on the X chromosome. Females can have clinically important disease, and an enzyme activity result in the reference range does not reliably exclude the diagnosis in a female.

The key is to keep three questions separate: Is the diagnosis established? Which organs are affected? What follow-up or treatment is appropriate for this individual? A single enzyme number cannot answer all three.

A simplified assessment pathway: normal enzyme activity in a female does not exclude Fabry disease.
A simplified assessment pathway: normal enzyme activity in a female does not exclude Fabry disease.

Open full-size illustration (new tab)

Which enzyme and organelle are involved?

GLA provides instructions for alpha-galactosidase A. Within lysosomes, the enzyme helps break down globotriaosylceramide, often abbreviated Gb3 or GL-3. Reduced effective processing can lead to accumulation and tissue injury. Lysosomes are therefore the organelles involved; Fabry disease is not primarily a mitochondrial disorder. Read the MedlinePlus GLA explanation.

Which features can lead to investigation?

Possible manifestations include pain in the hands or feet, altered sweating, gastrointestinal symptoms, characteristic skin or eye findings, and kidney, heart or neurological involvement. The combination, timing and severity vary. Later-onset presentations may not resemble the classic childhood description. These findings are not individually specific to Fabry disease. MedlinePlus describes the clinical spectrum.

A symptom list is useful for preparing a history, not for diagnosing yourself. Record what happened, at what age, whether it has been objectively assessed, and whether relatives have a confirmed diagnosis.

Why enzyme testing can miss affected females

Females generally have two X chromosomes, and patterns of X inactivation contribute to biological variability. An enzyme measurement from one sample does not necessarily represent the relevant biology across organs. Some heterozygous females have alpha-galactosidase A activity within the laboratory’s reference range. GeneReviews explains why molecular testing is central to diagnosis in females.

Fictional teaching example. A woman has a parent with a confirmed pathogenic GLA variant. Her enzyme activity is reported as normal. The correct next discussion is whether appropriate testing for the familial variant has been performed—not whether the enzyme result has automatically closed the question.

How the main tests fit together

Test or assessmentMain contributionImportant limitation
Alpha-galactosidase A activityBiochemical evidence about enzyme functionA normal result is insufficient to exclude Fabry disease in females
GLA analysisIdentifies and classifies relevant genetic findingsA VUS is not a confirmed diagnosis
Biomarkers such as lyso-Gb3Additional biochemical context where appropriateInterpretation depends on the person, assay and clinical question
Organ assessmentDefines current disease burden and care needsA genetic result alone cannot replace it

The Mayo Clinic Laboratories testing algorithm illustrates different entry points for biochemical and molecular assessment. Clinicians should use their local validated pathway, with laboratory advice for unexpected or borderline findings.

Is Fabry disease X-linked dominant or recessive?

X-linked is the clearest starting description. A simple “recessive, so women are only carriers” explanation is inadequate: females with a pathogenic GLA variant can develop substantial manifestations. Labels should not obscure that clinical reality.

In the usual X-linked transmission model, a heterozygous mother has a 50% chance of passing the variant in each pregnancy. A father with the variant passes his X chromosome to his daughters and not to his sons. Transmission does not predict the timing or severity of disease. Our penetrance and expressivity guide explains that distinction.

Family testing and reproductive questions

Once a familial pathogenic variant has been identified, targeted testing can help clarify which relatives inherited it. Prenatal diagnosis and preimplantation genetic testing may be options in an appropriately assessed family. Discuss these before pregnancy where possible, including what testing can establish and what uncertainty about future severity remains. A genetics professional can explain availability, timing and personal choices.

What if the report says “uncertain significance”?

A GLA VUS should prompt careful interpretation rather than automatic labelling of the person or family. The team may review the phenotype, biochemical findings, family data and published evidence. Avoid turning an uncertain variant into a firm diagnosis through repeated mention in correspondence.

Fictional teaching example. A panel finds a GLA VUS in someone with nonspecific fatigue. A discussion that starts “You have Fabry disease” runs ahead of the evidence. A more accurate record separates the unresolved variant from the symptoms and states which additional information could resolve the question.

Prepare for a specialist appointment

  • Bring the exact GLA result and full enzyme report, including sample type.
  • Bring the affected relative’s report if family testing is the reason for referral.
  • List relevant assessments of the heart, kidneys and nervous system.
  • Ask which findings establish diagnosis and which guide monitoring.
  • Ask who will coordinate follow-up and family communication.

Use our disease finder, variant worksheet and care finder to organize information for that conversation.